Sunshine Biopharma gets Canadian approval for generic Enalapril
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market
August 19, 2026 9:01 AM EDTGlobal anti-hypertensive drug market projected to reach $37.24 billion by 2034
Enalapril is a widely prescribed ACE inhibitor used to treat hypertension, heart failure and left ventricular dysfunction
Sunshine Biopharma expects Enalapril tablets in four dosage strengths to begin shipping to Canadian pharmacies by year-end 2026
FORT LAUDERDALE, FL / ACCESS Newswire / August 19, 2026 / Sunshine Biopharma Inc. (NASDAQ: SBFM) (the "Company"), a leading pharmaceutical... More
